Posts By :

Michael

Lysogene: conversion of the safeguard proceedings into reorganization proceedings

Lysogene: conversion of the safeguard proceedings into reorganization proceedings 150 150 Lysogene

Paris, France — 25 January 2023 at 08:00 am CET —Lysogene (FR0013233475 – LYS), a phase…

Lysogene: launch of a process to find buyers or investors and request for conversion of safeguard proceedings into reorganization proceedings

Lysogene: launch of a process to find buyers or investors and request for conversion of safeguard proceedings into reorganization proceedings 150 150 Lysogene

Paris, France — 6 January 2023 at 05:00 pm CET —Lysogene (FR0013233475 – LYS), a…

Lysogene announces the opening of a safeguard proceeding

Lysogene announces the opening of a safeguard proceeding 150 150 Lysogene

Paris, France — 14 December 2022 at 08:00 am CET — Lysogene (FR0013233475 – LYS),…

Lysogene announces the request for the opening of a safeguard proceeding

Lysogene announces the request for the opening of a safeguard proceeding 150 150 Lysogene

Paris, France — 6 December 2022 — Lysogene (FR0013233475 – LYS), a phase 3 gene…

Lysogene Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis

Lysogene Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis 150 150 Lysogene

Completion of treatment and 6 months follow-up for the last patient enrolled in Stage 1…

Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study

Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study 150 150 Lysogene

In the cohort of patients enrolled before the age of 30 months, a statistically significant…

Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022

Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022 150 150 Lysogene

Live webcast to be hosted on Wednesday, November 23, 2022 at 1:30 pm CET Paris,…

Lysogene Reports its Cash Position as of 30 September 2022

Lysogene Reports its Cash Position as of 30 September 2022 150 150 Lysogene

Cash and cash equivalents of €6.1 million[1] as of 30 September 2022 Paris, France —…

Lysogene Reports First Half 2022 Financial Results

Lysogene Reports First Half 2022 Financial Results 150 150 Lysogene

Full data analysis of AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in MPS…

Lysogene: New Board of Directors

Lysogene: New Board of Directors 150 150 Lysogene

Paris, France —16 September 2022 at 8:00 am CET — Lysogene (FR0013233475 – LYS), a…

  • 1
  • 2

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.